Progenics Pharmaceuticals
(PGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2000 | 12-1999 | 09-1999 | 06-1999 | 03-1999 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,472 | -490 | -2,020 | -3,510 | -240 |
| Depreciation Amortization | 294 | 910 | 600 | 370 | 180 |
| Accounts receivable | 565 | 488 | N/A | N/A | N/A |
| Other Working Capital | -1,247 | -440 | -2,130 | -440 | -1,320 |
| Other Operating Activity | -284 | 2,122 | 2,340 | 2,100 | 180 |
| Operating Cash Flow | $-2,144 | $2,590 | $-1,210 | $-1,480 | $-1,200 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -7,265 | -33,579 | N/A | N/A | N/A |
| PPE Investments | -88 | -1,040 | -700 | -440 | -200 |
| Other Investing Activity | 0 | -1 | -530 | 640 | -130 |
| Investing Cash Flow | $-7,353 | $-34,620 | $-1,230 | $200 | $-330 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -96 | -108 | N/A | N/A | N/A |
| Common Stock Issued | 1,238 | 41,907 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 0 | 770 | 230 | 100 |
| Financing Cash Flow | $1,142 | $41,800 | $770 | $230 | $100 |
| Beginning Cash Position | 24,213 | 14,430 | 14,430 | 14,430 | 14,430 |
| End Cash Position | 15,858 | 24,210 | 12,750 | 13,380 | 13,000 |
| Net Cash Flow | $-8,355 | $9,770 | $-1,680 | $-1,050 | $-1,430 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,144 | 2,590 | -1,210 | -1,480 | -1,200 |
| Capital Expenditure | -88 | -1,043 | N/A | N/A | N/A |
| Free Cash Flow | -2,232 | 1,547 | -1,210 | -1,480 | -1,200 |